Shaida Ouladan: Chimeric Antigen Receptor-T Cells in Colorectal Cancer
Shaida Ouladan, a Molecular Pathology Scientist, shared a recent article on LinkedIn:
“I’m thrilled to share that our latest article, ‘Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy’, is now published in the Journal of Clinical Oncology (JCO) American Society of Clinical Oncology (ASCO).
In this work, we discuss the transformative potential of CAR-T cell therapy for colorectal cancer (CRC) and explore:
Ongoing Clinical Trials that investigate innovative strategies like dual-targeting and armored CAR-T cells to tackle the unique challenges of solid tumors.
The critical role of target selection (e.g., GUCY2C, LGR5, and CEA) and how the tumor’s histopathology impacts CAR-T cell therapy outcomes.
How obstacles such as the immunosuppressive Tumor Microenvironment, antigen loss, and physical barriers (like fibrosis) influence treatment efficacy.
This paper highlights CAR-T cell therapy application in advancing Precision Oncology for CRC, with the potential to reshape its treatment landscape.”
Authors: Shaida Ouladan and Elias Orouji
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023